The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia.
The post Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression appeared first on MedCity News.
Claude Code Source Leaked via npm Packaging Error, Anthropic Confirms
Anthropic on Tuesday confirmed that internal code for its popular artificial intelligence (AI) coding assistant, Claude Code, had been inadvertently released due to a human
